72.6 F
New York
Monday, May 17, 2021

NeoGenomics [NASDAQ: NEO] Announces Acquisition of Inivata Ltd

Must read

Oaktree [NASDAQ: OCSL] Announces Pricing of Underwritten Public Offering

Oaktree Specialty Lending Corporation disclosed that it has set the price of an underwritten public offering of $350.0 million aggregate principal amount of...

Black.one Introduces Cryptocurrency Exchange Venture with $10B in Funding

Black.one has disclosed Tuesday that it has launched Bullish Global. Bullish Global is a subsidiary of Black.one. It is a new blockchain-based cryptocurrency exchange...

Pfizer-BioNTech COVID-19 Vaccine Gets FA Approval for Emergency Use in Adolescents

Pfizer Inc. and BioNTech SE disclosed that its COVID-19 vaccine has got the FDA approval for its COVID-19 vaccine. After the approval,...

Soliton [NASDAQ: SOLY] to be Acquired by Allergan Aesthetics

Soliton, Inc. disclosed Monday that it has inked an agreement with Allergen Aesthetics. As per the agreement, Allergen Aesthetics will buy Soliton. Allergen...

NeoGenomics, Inc. [NASDAQ: NEO] revealed Wednesday that it has decided to purchase Inivata Ltd. Inivata will grow into a liquid biopsy-centered division together with increasing clinical, pharma, and informatics divisions of NeoGenomics. NeoGenomics has a successful track record of market share. It advances by providing a trusted diagnostic testing collaborator for oncologists, pathologists, and biopharma.

Furthermore, NeoGenomics has spent a good portion of the last year working in collaboration with experts at Inivata. It also oversees positive due care on the business and its top liquid biopsy platform technology. Current Inivata CEO, Clive Morris, will serve as the President of Inivata. He will give a report to Mark Mallon, CEO of NeoGenomics.

Acquisition Benefits

This acquisition is beneficial for the firm as it speeds up the long-term expansion rate with an acceptance of liquid biopsy for therapy choice and MRD within a community setting over time. Moreover, this deal will provide more market options to NEO. Additionally, NEO will be able to exploit the current BioPharma workforce of 15 people. It will offer RaDaR to around 150 current clients comprising all 25 of the top 25 BioPharma firms around the globe.

Transaction Details

The buying is followed by a $25 million minority equity funding by NEO in Inivata in May 2020, at which time NeoGenomics had been granted a fixed price option to buy the rest of Inivata for $390 million prior to December 31, 2021. The cash buying price will be financed with balance sheet cash and through a private placement of equity, with the expected gross profit of $200 million, directed by a group of institutional investors comprising legacy Inivata shareholders, current investors of NEO, and a number of top oncology-focused professional stakeholders.

More articles

Latest article

Elon Musk’s SpaceX to Roll Out Dogecoin-Backed Satellite to the Moon in 2022

Elon Musk’s SpaceX has decided to recognize Dogecoin as payment to roll out its “DOGE-1 Mission to the Moon”. The mission is going to...

SBI CEO Yoshitaka Kitao Reveals Ripple to Go Public after its Legal Battle with the SEC is Over

CEO of Japanese financial services company SBI Holdings, Yoshitaka Kitao disclosed that Ripple has opted for an option to go public once its legal...

Coinbase Pro Announces it will be Listing Internet Computer’s ICP

Coinbase Pro cryptocurrency exchange has disclosed that it has decided to list ICP once it goes live. ICP is the governance token of the...

WISeKey [NASDAQ: WKEY] Gets Investment to finance its TrustNFT.IO NFT Platform

WISeKey International Holding AG disclosed Friday that it has inked a term-sheet to enter into an unsecured short-term loan and the issuance and...

Moderna [NASDAQ: MRNA] Inks Supply Agreement with Switzerland

Moderna, Inc. disclosed that it has inked a supply agreement on Thursday with the Swiss Federal Government. As per the agreement, Moderna Inc...

TeraBlock Will Have its Own BSCPad IDO Soon

TeraBlock which is a project making a platform for automated cryptocurrency portfolio management disclosed that it is preparing for an initial DEX offering (IDO)...

Why Chiasma [NASDAQ: CHMA] Stock is Skyrocketed?

Shares of Chiasma, Inc. surged 46.48% during the trading session of Wednesday. Chiasma has disclosed the financial results for the Q1 completed March...

NeoGenomics [NASDAQ: NEO] Announces Acquisition of Inivata Ltd

NeoGenomics, Inc. revealed Wednesday that it has decided to purchase Inivata Ltd. Inivata will grow into a liquid biopsy-centered division together with increasing...